First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
First Tracks Biotherapeutics reported Q1 2026 financial results following its April 20 spin-off from AnaptysBio, ending the quarter with approximately $248 million in cash and equivalents. The company posted a net loss of $50.5 million, driven by $34 million in R&D and $18.9 million in G&A expenses, which include allocations from the separation process. Management highlighted a two-year cash runway to advance lead asset ANB033 through Phase 1b trials in celiac disease and eosinophilic esophagitis, with data expected in late 2026 and mid-2027.
Key figures
- Eps
- 0
- Revenue
- 0
- Guidance
- Two-year cash runway to advance ANB033 through Phase 1b data
- Total assets
- 290576000
- Net loss q1 2026
- 50484000
- Rd expenses q1 2026
- 33955000
- Total cash position
- 180000000
- Cash and equivalents
- 248469000
- G a expenses q1 2026
- 18856000
- Short term investments
- 37986000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.